References
- Delmas P D. Clinical use of biochemical markers of bone remodeling in osteoporosis. Bone 1992; 13: 517–21
- Eriksen E F., Brixen K, Charles P. New markers of bone metabolism: Clinical use in metabolic bone disease. Europ J Endoc 1995; 132: 251–63
- Delmas P D. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 1990; 19: 1–18
- Robins S P., Stewart P, Astbury C, Bird H A. Measurement of the cross-linking compound, pyridinoline, in urine as an index of collagen degradation. Ann Rheum Dis 1986; 45: 969–73
- Demers L M., Kleerekoper M. Editorial: Recent advances in biochemical markers of bone turnover. Clin Chem 1994; 40: 1994–5
- Eyre D R., Paz M A., Gallop P M. Crosslinking in collagen and elastin. Ann Rev Biochem 1984; 53: 717–48
- Seibel M J., Robins S P., Bilezikian J P. Urinary pyridinium cross-links of collagen: Specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 1992; 3: 263–70
- Beardsworth L J., Eyre D R., Dickson I R. Changes with age in the urinary excretion of lysyl- and hydroxylysyl-pyridinoline: Two new markers of bone collagen turnover. J Bone Miner Res 1990; 5: 671–6
- Robins S P. An enzyme-linked immunoassay for the collagen cross-link pyridinoline. Biochem J 1982; 207: 617–20
- Seyedin S M., Kung V T., Daniloff Y N., Hesley R P., Gomez B, Nielsen L A., Rosen H N., Zuk R F. Immunoassay for urinary pyridinoline: The new marker of bone resorption. J Bone Miner Res 1993; 8: 635–41
- Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen; a new marker of bone degradation. Clin Chem 1993; 39: 635–40
- Hanson D A., Weis M-A E., Bollen A-M, Maslan S L., Singer F R., Eyre D R. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked, N-telopeptides in urine. J Bone Miner Res 1992; 7: 1251–8
- Apone S, Fevold K, Lee M, Eyre D. A rapid method for quantifying osteoclast activity in vitro. J Bone Miner Res 1994; 9(Suppl. 1)178
- Garnero P, Shih W J., Gineyts E, Karpf D B., Delmas P D. Comparison of new biochemical markers of bone turnover in late post-menopausal osteoporotic women in response to alendronate therapy. J Clin Endocrinol Metab 1994; 79: 1693–1700
- Rosen H N., Dresner-Pollak R, Moses A C., Rosenblatt M, Zeind A J., Clemens J D., Greenspan S L. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994; 54: 26–9
- Bonde M, Qvist P, Fledelius C, Riis B J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994; 40: 2022–5
- Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas P D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995; 10: 641–9
- Gertz B J., Shao P, Hanson D A., Quan H, Harris S T., Genant H K., Chesnut C H., III, Eyre D R. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994; 9: 135–42
- Ezzat S, Melmed S, Endrew D, Eyre D R., Singer F R. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 1993; 76(6)1452–7
- Bollen A-M, Eyre D R. Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 1994; 15: 31–4
- Blumsohn A, Herrington K, Hannon R A., Shao P, Eyre D R., Eastell R. The effect of calcium supplementation on the circadian rhythm of bone collagen degradation. J Clin Endocrinol Metab 1994; 79: 730–5
- Yamauchi M, Katz E P. The post-translational chemistry and molecular packing of mineralizing tendon collagens. Connect Tissue Res 1993; 29: 81–98
- Eyre D R., Dickson I R., van Ness K. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyri-dinium residues. Biochem J 1988; 252: 495–500